Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level IV

Purpose/Objective: This is the first report of toxicity outcomes on dose level IV (74 Gy) on RTOG 9406 for stage T1,2 adenocarcinoma of the prostate. Materials/Methods: 262 patients were entered on this cooperative group, phase I/II dose escalation trial of 3DCRT for localized carcinoma of the prostate to a dose of 74 Gy (Level IV). 256 patients at this dose are analyzable for toxicity. The daily fraction size was 2 Gy and was prescribed to the...